NCT04239092 2025-07-179-ING-41 in Pediatric Patients With Refractory Malignancies.Actuate Therapeutics Inc.Phase 1 Terminated40 enrolled
NCT02502708 2020-06-04Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain TumorsLumos PharmaPhase 1 Completed81 enrolled